SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending due to its association as Grok AI's dog and a potential connection to Elon Musk, fueling speculation within the AI meme coin sector. Community members are actively discussing its strong holder base, zero transaction taxes, and potential for significant growth during the anticipated altseason. The focus is on its potential as a community-owned gem on Ethereum.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community discusses its potential to break key resistance levels and make a parabolic move, with some anticipating a squeeze on short positions. Optimism is fueled by observations of coins leaving exchanges and a sense that the market is shifting away from altcoins. Broader conversations touch on the impact of potential government shutdowns and historical performance trends.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending, and the community is actively engaging with the classic 'What's UpDog?' joke, driving its visibility. Built on Solana and listed on Jupiter Strict List, this joke-meta coin has maintained a dedicated community for over a year, focusing on community and memetic appeal.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial results for its drug sonelokimab in treating hidradenitis suppurativa, with the community actively discussing its potential as a best-in-class treatment. Some investors speculate about a possible acquisition, while others are wary of a potential public offering. The stock's high short interest adds fuel to the conversation around its potential for significant price movement.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as the community discusses its potential breakout and accumulation at current prices, with some anticipating a significant upward move. Bullish sentiment seems to be fueled by discussions around altcoin season and NEAR's position in the AI crypto space. There's also chatter about potential partnerships and advancements in NEAR's underlying technology contributing to the positive outlook.

Pump.fun

$PUMP.X is trending as traders discuss potential for significant gains and monitor entry points, while some caution about corrections. The community highlights the platform's buyback program and the organic growth of associated tokens like $WAGMI.X, emphasizing the potential for "tokenized positivity" within the Solana ecosystem.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW.X is trending as the community rallies around the 'crow with knife' meme, calling it the only option for generational wealth. Discussions highlight its strong community, deflationary mechanisms, and expansion across multiple chains. The focus remains on community engagement and the potential for significant growth within the meme coin sector.

Doodles is a next-generation entertainment company focused on immersive storytelling through the creation and distribution of live and digital experiences, original content, and lifestyle products.  Doodles mission is to define the standard for immersive storytelling and color the world with joy.

Doodle Inu

Doodle Inu ($DOOD.X) is trending as the community rallies around its potential, with some eyeing a push towards the 50 mark and beyond.  Enthusiasm is fueled by comparisons to other meme coins and a newly launched dApp that allows users to create and upload their own Doodle Inu-themed NFTs. Some community members cite endorsements from crypto influencers and potential collaborations as further catalysts.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas is trending, with community members highlighting its recent listing on MEXC and comparing it to other tokens like PENGU. Discussions revolve around potential upcoming announcements and the project's strong fundamentals. Some users are also discussing which wallets they prefer to hold PANDU.X.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending amid renewed investor optimism, fueled by strong partnerships and expectations for upcoming earnings. The community is closely watching for continued growth in QNX, a key software platform, and potential revenue from existing royalty backlog.  Many believe a significant breakout is imminent, driven by the company's shift towards cybersecurity and IoT.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock following news of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">$9.1 billion acquisition</a> by French pharmaceutical giant Sanofi.The stock closed at $127.79 on Monday, up 26.1% for the day. After-hours trading showed a slight decline of 0.1% to $127.67.TD Cowen analyst Marc Frahm lowered the stock rating to ‘Hold’ from ‘Buy’ and established a price target of $130 based on the acquisition terms.&nbsp;JPMorgan reduced its rating to ‘Neutral’ from ‘Overweight’ and adjusted its target price to $129 from $130.Wolfe Research reduced Blueprint's rating to ‘Peer Perform’ from ‘Outperform’ by noting that the deal values Blueprint at $129 per share.&nbsp;Oppenheimer lowered its stock rating to ‘Perform’ from ‘Outperform,’ while describing the agreement as a “solid outcome for shareholders.”Scotiabank reduced its stock rating to ‘Sector Perform’ from ‘Outperform,’ while establishing a target price of $135.&nbsp;Wedbush assigned a $129 target after downgrading Blueprint to ‘Neutral’, while Needham downgraded it to ‘Hold.’Blueprint Medicines shareholders will receive one non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR, contingent on&nbsp;achieving future development and regulatory milestones for BLU-808.BLU-808 is an investigational oral inhibitor targeting wild-type KIT, which plays a role in mast cell activation involved in inflammatory diseases, including chronic urticaria.Including these potential payments, the total equity value of the Sanofi acquisition rises to approximately $9.5 billion on a fully diluted basis.Sanofi CEO Paul Hudson said this acquisition moves their rare and immunology portfolios forward.Sanofi’s earnings and gross margin will benefit from the transaction after 2026, while the company’s financial guidance for 2025 remains unaffected.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the price movement as a positive surprise, reporting a roughly 30% gain on their investment,&nbsp;noting this was better than recent returns on SpringWorks Therapeutics, but lower than several earlier buyouts this year.&nbsp;<stembedurl>https://stocktwits.com/Jackie_O_/message/616535057</stembedurl>Another user said that increased European pharma purchases of U.S. companies might be a strategy to gain favor with the Trump administration.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>Blueprint Medicines’&nbsp;stock has risen 46.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Blueprint Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Blueprint Medicines Stock  Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith

Analysts revised price targets near the deal’s $129-per-share valuation.

Equity

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines 

Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical company Sanofi (SNY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541">announced</a> that it would acquire Blueprint in a bid to expand its rare immunological disease portfolio.Under the terms of the deal, Sanofi will pay $129 per share in cash at closing, representing an equity value of approximately $9.1 billion.The upfront purchase price represents a 27% premium to Blueprint’s closing price on Friday of $101.35.In addition, Blueprint shareholders will receive one non-tradable contingent value right (CVR), which will entitle them to receive two potential milestone payments of $2 and $4 per CVR for the achievement of future milestones for BLU-808, an investigational therapy with the potential to treat a broad range of diseases in immunology.The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis, Sanofi said. The firm added that it expects the transaction to be completed in the third quarter of 2025.The acquisition includes Ayvakit or Ayvakyt (Avapritinib), the only approved medicine for rare immunology diseases, advanced and indolent systemic mastocytosis (ASM &amp; ISM), in addition to Elenestinib, an investigational medicine for systemic mastocytosis, as well as BLU-808.Sanofi CEO Paul Hudson said that the company retains a “sizeable capacity” for further acquisitions. The firm expects the Blueprint acquisition not to have a significant impact on its financial guidance for 2025 but to be immediately accretive to gross margin and to business operating income and EPS after 2026.Last month, Sanofi said it is looking to invest at least $20 billion in the U.S. through 2030. The company also announced it would acquire U.S.-based Vigil Neuroscience, Inc. (VIGL) for about $470 million soon after.On Stocktwits, retail sentiment around Blueprint Medicines Corporation jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_06_38_AM_png_dab4b84360.webp" alt="BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, retail sentiment around Sanofi stayed unmoved within the ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_14_54_AM_png_d728df50b2.webp" alt="SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="65"><figcaption>SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes U.S. pharmaceutical companies will receive acquisition offers from their European counterparts.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>While <a href="https://stocktwits.com/symbol/BPMC">BPMC stock</a> is up by about 16% this year, <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> is up by over 2%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-commits-400-million-to-boost-swiss-ai-cloud-ecosystem/chkoUr7RbHb">Microsoft Commits $400M To Boost Swiss AI, Cloud Ecosystem: Retail Mood Stays ‘Bearish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results PR Newswire CAMBRIDGE, Mass., Feb. 13, 2025 -- Achieved...

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on...

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth PR Newswire CAMBRIDGE...

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass...

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting Blueprint Medicines' Continued Leadership in Redefining...

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities.

 Latest Ratings for BPMC...

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Blueprint Medicines Corp

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.17	--	--	N/A
Q2 '25	-$0.47	--	--	N/A
Q1 '25	-$0.49	$0.01	102.06%	BEAT
Q4 '24	-$0.68	-$0.79	-16.72%	MISSED
Q3 '24	-$0.96	-$0.89	7.39%	BEAT

BPMC
Blueprint Medicines Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest BPMC News

BPMC Blueprint Medicines Corp